Ivosidenib (IVO) prior to hematopoietic cell transplant (HCT) for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML) who cannot tolerate intensive chemotherapy (IC) Meeting Abstract
| Authors: | DiNardo, C. D.; Stein, E. M.; Pigneux, A.; Altman, J. K.; Collins, R.; Erba, H. P.; Watts, J. M.; Uy, G. L.; Wu, B.; Choe, S.; Kapsalis, S. M.; Liu, H.; Winkler, T.; Roboz, G. J.; de Botton, S. |
| Abstract Title: | Ivosidenib (IVO) prior to hematopoietic cell transplant (HCT) for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML) who cannot tolerate intensive chemotherapy (IC) |
| Meeting Title: | 8th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | refractory; hematopoietic cell transplantation; aml; relapsed; acute myeloid leukemia; ivosidenib |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 20 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Sep 9-12 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-09-01 |
| Start Page: | S197 |
| End Page: | S198 |
| Language: | English |
| ACCESSION: | WOS:000564055100115 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(20)30745-X |
| Notes: | Meeting Abstract: AML-262 -- Due to COVID-19 pandemic, the conference was held virtually -- Source: Wos |
